KP Tissue Inc. (KPT) (TSX: KPT) reports the Q4 2023 and full year
2023 financial and operational results of KPT and Kruger Products
Inc. (Kruger Products). Kruger Products is Canada's leading
manufacturer of quality tissue products for the Consumer market
(Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and
BonterraTM) and the Away-From-Home (AFH) market and continues to
grow in the U.S. Consumer tissue business with the White Cloud®
brand and premium private label products. KPT currently holds a
12.9% interest in Kruger Products.
Kruger Products Q4 2023 Business and Financial
Highlights
- Revenue was $482.3 million in Q4
2023 compared to $458.1 million in Q4 2022, an increase of $24.2
million or 5.3%.
- Adjusted EBITDA1 was $61.2 million in
Q4 2023, compared to $44.4 million in Q4 2022, an increase of
37.9%.
- Net income was $16.5 million in Q4
2023 compared to $16.0 million in Q4 2022, an increase of $0.5
million.
- Declared a quarterly dividend of
$0.18 per share to be paid on April 15, 2024.
- Facial tissue line in the Sherbrooke
Expansion Project started up successfully in February 2024.
- Announced a 25% increase in facial
production at the Gatineau plant on March 5, 2024 with a $14.5
million investment.
Kruger Products Full Year 2023 Financial
Highlights
- Revenue was $1,873.0 million in Fiscal 2023 compared to
$1,681.4 million in Fiscal 2022, an increase of $191.6 million or
11.4%.
- Adjusted EBITDA1 was $238.6 million in Fiscal 2023, compared to
$116.0 million in Fiscal 2022, an increase of 105.7%.
- Net loss was $5.3 million in Fiscal 2023 compared to $56.9
million in Fiscal 2022, a decrease in the loss of $51.6
million.
“We are pleased with our financial results in
fiscal 2023, highlighted by record sales of $1.9 billion and record
Adjusted EBITDA of $238.6 million driven by many positive factors,”
stated KP Tissue’s Chief Executive Officer, Dino Bianco. “Overall,
our business benefited from robust volume, positive margin
management with continued volatile costs, and strong operational
efficiency across our network.”
“In our Consumer segment, we gained market share
within the facial tissue and paper towel categories, while
improving our share trend on bathroom tissue. We also stepped up to
support and supply our Scotties facial tissue to customers and
consumers given the exit of Kleenex from the Canadian grocery
market. Our Away-From-Home business continued to deliver
sustainable results with another strong Adjusted EBITDA quarter and
year.”
“In the fourth quarter, our underlying results
remained solid with Adjusted EBITDA growing 37.9% year-over-year to
$61.2 million, despite strategically increasing investments in
marketing and maintenance to enable us to enter 2024 in a stronger
competitive position. Looking ahead, we plan to manage our margins
amid rising costs, continue to invest in our brands, grow our
facial tissue position, and implement a successful start-up of our
Sherbrooke Expansion,” Mr. Bianco concluded.
Outlook for Q1 2024
For the first quarter of 2024, we expect margins
to remain consistent and Adjusted EBITDA1 to be in a similar range
to Q4 2023.
Kruger Products Q4 2023 Financial
ResultsRevenue was $482.3 million in Q4 2023 compared to
$458.1 million in Q4 2022, an increase of $24.2 million or 5.3%.
The increase in revenue was primarily due to higher sales volume,
partially offset by increased promotional spending compared to the
prior year quarter.
Cost of sales was $400.5 million in Q4 2023
compared to $416.4 million in Q4 2022, a decrease of $15.9 million
or 3.8%. Manufacturing costs decreased due primarily to lower pulp
and other input costs resulting from moderating inflation and
productivity improvements in plant operations, which were only
partially offset by higher volume. Freight costs were lower
compared to Q4 2022 as supply constraints and inflation moderated,
while warehousing costs increased as a result of additional
logistics network costs. As a percentage of revenue, cost of sales
was 83.0% in Q4 2023 compared to 90.9% in Q4 2022.
Selling, general and administrative (SG&A)
expenses were $50.3 million in Q4 2023 compared to $30.6 million in
Q4 2022, an increase of $19.7 million or 64.4%. The increase was
primarily due to significantly higher advertising and IT spend in
the quarter, higher personnel and selling expenses to support
additional sales volume, and a loss on disposal of fixed assets. As
a percentage of revenue, SG&A expenses were 10.4% in Q4 2023
compared to 6.7% in Q4 2022.
Adjusted EBITDA1 was $61.2 million in Q4 2023
compared to $44.4 million in Q4 2022, an increase of $16.8 million
or 37.9%. The significant increase was primarily due to higher
sales volume, lower pulp and other input costs, productivity
improvements in plant operations and lower freight costs, partially
offset by slightly lower selling prices, higher warehousing and
SG&A expenses.
Net income was $16.5 million in Q4 2023 compared
to $16.0 million in Q4 2022, an increase of $0.5 million. The
increase was primarily due to higher Adjusted EBITDA1, lower
depreciation expense and restructuring costs related primarily to
the shutdown of certain Memphis plant production assets in Q4 2022,
higher foreign exchange gains and lower interest expense, partially
offset by the change in the amortized cost of Partnership Units
Liability in Q4 2022, a loss on sale of fixed assets, higher income
tax expense and a loss from non-controlling interest.
Kruger Products 2023 Financial
ResultsRevenue was $1,873.0 million in Fiscal 2023
compared to $1,681.4 million in Fiscal 2022, an increase of $191.6
million or 11.4%. The increase in revenue was primarily due to
higher sales volume along with the favourable impact of selling
price increases implemented across all segments and regions during
Fiscal 2022. Revenue was also favourably impacted by foreign
exchange fluctuations on U.S. dollar sales.
Adjusted EBITDA1 was $238.6 million in Fiscal
2023 compared to $116.0 million in Fiscal 2022, an increase of
$122.6 million or 105.7%. The significant increase was primarily
due to the favourable impact of selling price increases implemented
in Fiscal 2022 along with higher sales volume, lower pulp prices,
improvements in Memphis operations and lower freight costs,
partially offset by other input cost inflation compared to Fiscal
2022, higher manufacturing overhead spending, and higher
warehousing and SG&A expenses along with the unfavourable
impact of foreign exchange fluctuations.
Net loss was $5.3 million in Fiscal 2023
compared to $56.9 million in Fiscal 2022, a decrease in the loss of
$51.6 million. The decrease in the loss was primarily due to higher
Adjusted EBITDA1, a lower foreign exchange loss, lower interest and
depreciation expenses and lower consulting and restructuring costs,
partially offset by higher income tax expense, the change in the
amortized cost of Partnership Units Liability in Fiscal 2022, a
loss on sale of fixed assets and a loss from non-controlling
interest.
Kruger Products Q4 2023
LiquidityTotal liquidity, representing cash and
availability under the revolving credit agreements, was $326.7
million as of December 31, 2023. In addition, $14.9 million of cash
was held for the Sherbrooke Expansion Project.
KPT Q4 2023 Financial
ResultsKPT had net income of $2.0 million in Q4 2023.
Included in net income was $2.2 million representing KPT’s share of
Kruger Products’ net income, a dilution gain of $0.3 million,
depreciation expense of $0.3 million related to adjustments to
carrying amounts on acquisition and an income tax expense of $0.2
million.
KPT 2023 Financial ResultsKPT
had a net loss of $4.9 million in Fiscal 2023. Included in the net
loss was $0.7 million representing KPT’s share of Kruger Products’
net loss, a dilution gain of $1.1 million, depreciation expense of
$1.2 million related to adjustments to carrying amounts on
acquisition and an income tax expense of $4.1 million.
Dividends on Common SharesThe
Board of Directors of KPT declared a quarterly dividend of $0.18
per share to be paid on April 15, 2024 to shareholders of record at
the close of business on April 1, 2024.
Additional InformationFor
additional information please refer to Management’s Discussion and
Analysis (MD&A) of KPT and Kruger Products for the fourth
quarter and fiscal year ended December 31, 2023 available on SEDAR+
at www.sedarplus.ca or our website
at www.kptissueinc.com.
Fourth Quarter Results Conference Call
InformationKPT will hold its fourth quarter conference
call on Thursday, March 7, 2024 at 8:30 a.m. Eastern Time.
Via telephone: 1-888-664-6383 or 416-764-8650
Via the internet at: www.kptissueinc.com
Presentation material referenced during the conference call will
be available at www.kptissueinc.com.
A rebroadcast of the conference call will be
available until midnight, March 14, 2024 by dialing 1-888-390-0541
or 416-764-8677 and entering passcode 631417.
The replay of the webcast will remain available on the website
until midnight, March 14, 2024.
About KP Tissue Inc. (KPT)KPT
was created to acquire, and its business is limited to holding, a
limited equity interest in Kruger Products, which is accounted for
as an investment on the equity basis. KPT currently holds a 12.9%
interest in Kruger Products. For more information visit
www.kptissueinc.com.
About Kruger ProductsKruger
Products is Canada's leading manufacturer of quality tissue
products for household, industrial and commercial use. Kruger
Products serves the Canadian consumer market with such well-known
brands as Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan®
and BonterraTM. In the U.S., Kruger Products manufactures the White
Cloud® brand, as well as many private label products. The
Away-From-Home division manufactures and distributes high-quality,
cost-effective product solutions to a wide range of commercial and
public entities. Kruger Products has approximately 2,800 employees
and operates nine FSC® COC-certified (FSC® C-104904) production
facilities in North America. For more information
visit www.krugerproducts.ca.
Non-GAAP Financial MeasuresThis
press release uses certain non-GAAP financial measures which Kruger
Products believes provide useful information to management of
Kruger Products and the readers of the financial information in
measuring the financial performance and financial condition of
Kruger Products. These measures do not have a standardized meaning
prescribed by GAAP and therefore may not be comparable to similarly
titled measures presented by other companies. An example of such a
measure is Adjusted EBITDA. Adjusted EBITDA is not a measurement of
operating performance computed in accordance with GAAP and should
not be considered as a substitute for operating income, net income
or cash flows from operating activities computed in accordance with
GAAP. “Adjusted EBITDA” is calculated by Kruger Products as net
income (loss) before (i) interest expense and other finance costs,
(ii) income taxes, (iii) depreciation, (iv) amortization, (v) loss
(gain) on disposal of property, plant and equipment, (vi) foreign
exchange loss (gain), (vii) costs related to restructuring
activities, (viii) changes in amortized cost of Partnership units
liability, (ix) consulting costs related to operational
transformation initiatives and (x) corporate development related
costs. A reconciliation of Adjusted EBITDA to the relevant reported
results can be found in the Segment and Geographic Results table of
this news release.
Forward-Looking
StatementsCertain statements in this press release about
KPT’s and Kruger Products' current and future plans, expectations
and intentions, results, levels of activity, performance, goals or
achievements or any other future events or developments constitute
forward-looking statements. The words "may", "will", "would",
"should", "could", "expects", "plans", "intends", "trends",
"indications", "anticipates", "believes", "estimates", "predicts",
"likely" or "potential" or the negative or other variations of
these words or other comparable words or phrases, are intended to
identify forward-looking statements. The forward-looking statements
are based on certain key expectations and assumptions made by KPT
or Kruger Products, including the moderation of inflationary
pressure on input costs and continued inflationary pressure on
SG&A as labour, marketing and IT costs continue to rise.
Although KPT and Kruger Products believe that the expectations and
assumptions on which such forward-looking information is based are
reasonable, undue reliance should not be placed on the
forward-looking statements since no assurance can be given that
such expectations and assumptions will prove to be correct.
The outlook provided in respect of Adjusted
EBITDA1 for Q1 2024 is forward-looking information and is based on
the assumptions and subject to the risk and uncertainties referred
to below. The purpose of the outlook is to provide the reader with
an indication of management’s expectations, at the date of this
press release, regarding Kruger Products’ future financial
performance. Readers are cautioned that this information may not be
appropriate for other purposes.
Many factors could cause Kruger Products’ actual
results, level of activity, performance or achievements or future
events or developments (which could in turn affect the economic
benefits derived from KPT’s economic interest in Kruger Products),
to differ materially from those expressed or implied by the
forward-looking statements, including, without limitation, the
following factors, which are discussed in greater detail in the
“Risk Factors – Risks Related to Kruger Products’ Business” section
of the KPT Annual Information Form dated March 7, 2024 available on
SEDAR+ at www.sedarplus.ca: Kruger Inc.’s influence over
Kruger Products; Kruger Products’ reliance on Kruger Inc.;
consequences of an event of insolvency relating to Kruger Inc.;
risks associated with the ownership of the TAD Sherbrooke Project;
risks associated with the operation of the TAD Sherbrooke Project;
risks associated with the Sherbrooke Expansion Project; operational
risks; significant increases in input costs; reduction in supply of
fibre; increased pricing pressure and intense competition; Kruger
Products’ inability to innovate effectively; adverse economic
conditions; dependence on key retail trade customers; damage to the
reputation of Kruger Products or Kruger Products’ brands; Kruger
Products’ sales being less than anticipated; Kruger Products’
failure to implement its business and operating strategies; Kruger
Products’ obligation to make regular capital expenditures; Kruger
Products entering into unsuccessful acquisitions; Kruger Products’
dependence on key personnel; Kruger Products’ inability to retain
its existing customers or obtain new customers; Kruger Products’
loss of key suppliers; Kruger Products’ failure to adequately
protect its intellectual property rights; Kruger Products’ reliance
on third party intellectual property licenses; adverse litigation
and other claims affecting Kruger Products; material expenditures
due to comprehensive environmental regulation affecting Kruger
Products’ cash flow; Kruger Products’ pension obligations are
significant and can be materially higher than predicted if Kruger
Products Management’s underlying assumptions are incorrect; labour
disputes adversely affecting Kruger Products’ cost structure and
Kruger Products’ ability to run its plants; exchange rate and U.S.
competitors; Kruger Products’ inability to service all of its
indebtedness; exposure to potential consumer product liability;
covenant compliance; interest rate and refinancing risk; and risks
relating to information technology; cyber-security; insurance;
internal controls; and trade.
Readers should not place undue reliance on
forward-looking statements made herein. The forward-looking
information contained herein is expressly qualified in its entirety
by this cautionary statement. The forward-looking information
contained herein is made as of the date of press release and KPT
undertakes no obligation to publicly update such forward-looking
information to reflect new information, subsequent or otherwise,
unless required by applicable securities laws.
INFORMATION:
Francois ParoyanGeneral Counsel and Corporate SecretaryKP Tissue
Inc.Tel.: 905.812.6936francois.paroyan@krugerproducts.ca
INVESTORS:
Mike BaldesarraDirector of Investor RelationsKP Tissue Inc.Tel.:
905.812.6962IR@KPTissueinc.com
1 Adjusted EBITDA is a non-GAAP financial measure. Refer to the
Non-GAAP Financial Measures section of this news release for more
information on these measures
Kruger Products Inc. |
Consolidated Statements of Financial Position |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
|
December 31, 2022 |
|
|
|
$ |
|
|
$ |
|
Assets |
|
|
|
Current assets |
|
|
|
|
Cash and cash equivalents |
135,728 |
|
|
71,261 |
|
|
Restricted cash |
12,451 |
|
|
7,145 |
|
|
Trade and other receivables |
130,157 |
|
|
119,681 |
|
|
Receivables from related parties |
842 |
|
|
223 |
|
|
Inventories |
254,372 |
|
|
286,566 |
|
|
Income tax recoverable |
4,578 |
|
|
1,306 |
|
|
Prepaid expenses |
4,726 |
|
|
5,640 |
|
|
|
542,854 |
|
|
491,822 |
|
Non-current assets |
|
|
|
|
Property, plant and equipment |
1,421,650 |
|
|
1,294,838 |
|
|
Right-of-use assets |
84,866 |
|
|
81,715 |
|
|
Other long-term assets |
3,808 |
|
|
27,554 |
|
|
Pensions |
69,839 |
|
|
83,080 |
|
|
Goodwill |
152,021 |
|
|
152,021 |
|
|
Intangible assets |
26,852 |
|
|
30,027 |
|
|
Deferred income taxes |
23,740 |
|
|
95,711 |
|
Total assets |
2,325,630 |
|
|
2,256,768 |
|
|
|
|
|
|
Liabilities |
|
|
|
Current liabilities |
|
|
|
|
Trade and other payables |
400,385 |
|
|
279,425 |
|
|
Payables to related parties |
10,973 |
|
|
11,363 |
|
|
Dividends payable |
13,675 |
|
|
- |
|
|
Distributions payable |
- |
|
|
12,866 |
|
|
Current portion of long-term debt |
35,229 |
|
|
34,411 |
|
|
Current portion of lease liabilities |
27,154 |
|
|
28,349 |
|
|
Current portion of long-term payable to related party |
5,800 |
|
|
5,800 |
|
|
Current portion of provisions |
3,952 |
|
|
3,252 |
|
|
|
497,168 |
|
|
375,466 |
|
Non-current liabilities |
|
|
|
|
Long-term debt |
1,034,016 |
|
|
1,077,297 |
|
|
Long-term lease liabilities |
71,865 |
|
|
70,579 |
|
|
Long-term payable to related party |
35,580 |
|
|
39,042 |
|
|
Long-term provisions |
5,740 |
|
|
3,076 |
|
|
Pensions |
18,935 |
|
|
20,847 |
|
|
Post-retirement benefits |
48,699 |
|
|
43,739 |
|
|
Liabilities to non-equityholders |
1,712,003 |
|
|
1,630,046 |
|
|
Long-term portion of Partnership units
liability |
- |
|
|
133,551 |
|
Total liabilities |
1,712,003 |
|
|
1,763,597 |
|
|
|
|
|
|
Equity |
|
|
|
|
Share capital |
278,252 |
|
|
- |
|
|
Partnership units |
- |
|
|
494,459 |
|
|
Contributed surplus |
395,382 |
|
|
- |
|
|
Deficit |
(164,029 |
) |
|
(87,835 |
) |
|
Accumulated other comprehensive income |
81,011 |
|
|
86,547 |
|
|
Equity attributable to Kruger Products |
590,616 |
|
|
493,171 |
|
|
Non-controlling interest |
23,011 |
|
|
- |
|
Total equity |
613,627 |
|
|
493,171 |
|
Total equity and liabilities |
2,325,630 |
|
|
2,256,768 |
|
|
|
|
|
|
Kruger Products Inc. |
Consolidated Statements of Income
(Loss) |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-monthperiod endedDecember 31, 2023 |
|
|
3-monthperiod endedDecember 31, 2022 |
|
|
12-monthperiod endedDecember 31, 2023 |
|
|
12-monthperiod endedDecember 31, 2022 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
Revenue |
482,269 |
|
|
458,139 |
|
|
1,872,962 |
|
|
1,681,403 |
|
|
|
|
|
|
|
|
|
Expenses |
|
|
|
|
|
|
|
Cost of sales |
400,476 |
|
|
416,378 |
|
|
1,571,587 |
|
|
1,547,318 |
|
Selling, general and administrative expenses |
50,319 |
|
|
30,612 |
|
|
167,209 |
|
|
124,648 |
|
Restructuring costs, net |
274 |
|
|
3,543 |
|
|
1,574 |
|
|
4,550 |
|
|
|
|
|
|
|
|
|
Operating income |
31,200 |
|
|
7,606 |
|
|
132,592 |
|
|
4,887 |
|
|
|
|
|
|
|
|
|
Interest expense and other finance costs |
18,515 |
|
|
20,658 |
|
|
70,255 |
|
|
74,468 |
|
Other expense (income) |
(8,482 |
) |
|
(30,956 |
) |
|
(9,352 |
) |
|
3,373 |
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
21,167 |
|
|
17,904 |
|
|
71,689 |
|
|
(72,954 |
) |
|
|
|
|
|
|
|
|
Current tax expense (recovery) |
689 |
|
|
(97 |
) |
|
2,632 |
|
|
1,288 |
|
Deferred tax expense (recovery) |
1,916 |
|
|
2,005 |
|
|
70,776 |
|
|
(17,360 |
) |
|
|
|
|
|
|
|
|
Income tax expense (recovery) |
2,605 |
|
|
1,908 |
|
|
73,408 |
|
|
(16,072 |
) |
|
|
|
|
|
|
|
|
Net income (loss) including non-controlling
interest |
18,562 |
|
|
15,996 |
|
|
(1,719 |
) |
|
(56,882 |
) |
|
|
|
|
|
|
|
|
Net income attributable to non-controlling
interest |
2,026 |
|
|
- |
|
|
3,594 |
|
|
- |
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Kruger
Products |
16,536 |
|
|
15,996 |
|
|
(5,313 |
) |
|
(56,882 |
) |
|
|
|
|
|
|
|
|
Kruger Products Inc. |
Consolidated Statements of Cash Flows |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-monthperiod endedDecember 31, 2023 |
|
|
3-monthperiod endedDecember 31, 2022 |
|
|
12-monthperiod endedDecember 31, 2023 |
|
|
12-monthperiod endedDecember 31, 2022 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Cash flows from (used in) operating
activities |
|
|
|
|
|
|
|
Net income (loss) including non-controlling interest |
18,562 |
|
|
15,996 |
|
|
(1,719 |
) |
|
(56,882 |
) |
Items not affecting cash |
|
|
|
|
|
|
|
Depreciation |
26,691 |
|
|
32,008 |
|
|
96,996 |
|
|
98,452 |
|
Amortization |
1,106 |
|
|
1,142 |
|
|
4,377 |
|
|
4,419 |
|
Loss on sale of property, plant and equipment |
1,945 |
|
|
103 |
|
|
3,043 |
|
|
121 |
|
Gain on disposal of leased assets |
- |
|
|
- |
|
|
(488 |
) |
|
- |
|
Change in amortized cost of Partnership unit liability |
- |
|
|
(25,586 |
) |
|
- |
|
|
(25,586 |
) |
Foreign exchange loss (gain) |
(8,482 |
) |
|
(5,418 |
) |
|
(9,352 |
) |
|
28,911 |
|
Interest expense and other finance costs |
18,515 |
|
|
20,658 |
|
|
70,255 |
|
|
74,468 |
|
Pension and post-retirement benefits |
2,200 |
|
|
3,656 |
|
|
8,656 |
|
|
14,632 |
|
Provisions |
998 |
|
|
1,373 |
|
|
3,702 |
|
|
2,640 |
|
Income tax expense (recovery) |
2,605 |
|
|
1,908 |
|
|
73,408 |
|
|
(16,072 |
) |
Loss on sale of non-financial assets |
3 |
|
|
1 |
|
|
24 |
|
|
12 |
|
Total items not affecting cash |
45,581 |
|
|
29,845 |
|
|
250,621 |
|
|
181,997 |
|
|
|
|
|
|
|
|
|
Net change in non-cash working capital |
45,895 |
|
|
20,004 |
|
|
110,162 |
|
|
(65,241 |
) |
Contributions to pension and post-retirement benefit plans |
(1,098 |
) |
|
(2,638 |
) |
|
(8,537 |
) |
|
(15,192 |
) |
Provisions paid |
(862 |
) |
|
(150 |
) |
|
(4,305 |
) |
|
(4,153 |
) |
Income tax payments, net |
174 |
|
|
(49 |
) |
|
(1,834 |
) |
|
(1,806 |
) |
Net cash from operating activities |
108,252 |
|
|
63,008 |
|
|
344,388 |
|
|
38,723 |
|
|
|
|
|
|
|
|
|
Cash flows from (used in) investing
activities |
|
|
|
|
|
|
|
Purchases of property, plant and equipment |
(19,980 |
) |
|
(10,349 |
) |
|
(34,653 |
) |
|
(37,660 |
) |
Purchases of property, plant
and equipment and software related to the TAD Sherbrooke
Project |
(855 |
) |
|
(5,517 |
) |
|
(2,435 |
) |
|
(20,702 |
) |
Purchases of property, plant
and equipment related to the Sherbrooke Expansion Project |
(57,943 |
) |
|
(23,174 |
) |
|
(147,938 |
) |
|
(53,118 |
) |
Interest paid on credit
facilities related to the Sherbrooke Expansion Project, net |
(133 |
) |
|
51 |
|
|
(454 |
) |
|
(238 |
) |
Government assistance received |
- |
|
|
- |
|
|
1,250 |
|
|
1,023 |
|
Purchases of software |
(646 |
) |
|
(7 |
) |
|
(1,202 |
) |
|
(4,946 |
) |
Proceeds on sale of property, plant and equipment |
121 |
|
|
- |
|
|
2,586 |
|
|
1 |
|
Net cash used in investing activities |
(79,436 |
) |
|
(38,996 |
) |
|
(182,846 |
) |
|
(115,640 |
) |
|
|
|
|
|
|
|
|
Cash flows from (used in) financing
activities |
|
|
|
|
|
|
|
Proceeds from long-term debt, net |
43,411 |
|
|
(4,071 |
) |
|
130,954 |
|
|
244,255 |
|
Repayment of long-term debt |
(57,874 |
) |
|
(5,801 |
) |
|
(127,780 |
) |
|
(141,519 |
) |
Payment of deferred financing fees |
(494 |
) |
|
(218 |
) |
|
(899 |
) |
|
(3,036 |
) |
Payment of lease liabilities |
(9,984 |
) |
|
(6,850 |
) |
|
(30,819 |
) |
|
(28,113 |
) |
Change in Restricted cash |
(1,369 |
) |
|
(1,167 |
) |
|
(5,306 |
) |
|
(4,639 |
) |
Interest paid on long-term debt |
(15,109 |
) |
|
(15,750 |
) |
|
(49,390 |
) |
|
(51,948 |
) |
Payment to related party |
- |
|
|
- |
|
|
(5,700 |
) |
|
- |
|
Dividends paid, net |
(1,743 |
) |
|
- |
|
|
(6,988 |
) |
|
- |
|
Distributions paid, net |
- |
|
|
(1,731 |
) |
|
- |
|
|
(17,495 |
) |
Net cash used in financing activities |
(43,162 |
) |
|
(35,588 |
) |
|
(95,928 |
) |
|
(2,495 |
) |
|
|
|
|
|
|
|
|
Effect of exchange
rate changes on cash and cash equivalents held in foreign
currency |
(1,071 |
) |
|
714 |
|
|
(1,147 |
) |
|
2,154 |
|
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents during
the period |
(15,417 |
) |
|
(10,862 |
) |
|
64,467 |
|
|
(77,258 |
) |
|
|
|
|
|
|
|
|
Cash and cash equivalents - Beginning
of period |
151,145 |
|
|
82,123 |
|
|
71,261 |
|
|
148,519 |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - End
of period |
135,728 |
|
|
71,261 |
|
|
135,728 |
|
|
71,261 |
|
|
|
|
|
|
|
|
|
Kruger Products Inc. |
Segment and Geographic Results |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-monthperiod endedDecember 31, 2023 |
|
|
3-monthperiod endedDecember 31, 2022 |
|
|
12-monthperiod endedDecember 31, 2023 |
|
|
12-monthperiod endedDecember 31, 2022 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
Segment Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment Revenue |
|
|
|
|
|
|
|
Consumer |
400,867 |
|
|
378,814 |
|
|
1,551,157 |
|
|
1,394,052 |
|
AFH |
81,402 |
|
|
79,325 |
|
|
321,805 |
|
|
287,351 |
|
|
|
|
|
|
|
|
|
Revenue from external customers |
482,269 |
|
|
458,139 |
|
|
1,872,962 |
|
|
1,681,403 |
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
|
|
|
|
|
|
Consumer |
59,842 |
|
|
42,709 |
|
|
230,310 |
|
|
117,428 |
|
AFH |
5,714 |
|
|
5,690 |
|
|
20,792 |
|
|
7,375 |
|
Corporate and other costs |
(4,337 |
) |
|
(3,993 |
) |
|
(12,496 |
) |
|
(8,812 |
) |
|
|
|
|
|
|
|
|
Total Adjusted EBITDA |
61,219 |
|
|
44,406 |
|
|
238,606 |
|
|
115,991 |
|
|
|
|
|
|
|
|
|
Reconciliation to net income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
27,797 |
|
|
33,150 |
|
|
101,373 |
|
|
102,871 |
|
Interest expense and other finance costs |
18,515 |
|
|
20,658 |
|
|
70,255 |
|
|
74,468 |
|
Change in amortized cost of Partnership unit liability |
- |
|
|
(25,586 |
) |
|
- |
|
|
(25,586 |
) |
Loss on sale of property, plant and equipment |
1,945 |
|
|
103 |
|
|
3,043 |
|
|
121 |
|
Loss on sale of non-financial assets |
3 |
|
|
1 |
|
|
24 |
|
|
12 |
|
Other expense |
- |
|
|
48 |
|
|
- |
|
|
48 |
|
Restructuring costs, net |
274 |
|
|
3,543 |
|
|
1,574 |
|
|
4,550 |
|
Foreign exchange loss (gain) |
(8,482 |
) |
|
(5,418 |
) |
|
(9,352 |
) |
|
28,911 |
|
Consulting costs related to operational transformation
initiatives |
- |
|
|
3 |
|
|
- |
|
|
3,550 |
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
21,167 |
|
|
17,904 |
|
|
71,689 |
|
|
(72,954 |
) |
|
|
|
|
|
|
|
|
Income tax expense (recovery) |
2,605 |
|
|
1,908 |
|
|
73,408 |
|
|
(16,072 |
) |
|
|
|
|
|
|
|
|
Net income (loss) including non-controlling interest |
18,562 |
|
|
15,996 |
|
|
(1,719 |
) |
|
(56,882 |
) |
|
|
|
|
|
|
|
|
Geographic Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Canada |
274,843 |
|
|
262,335 |
|
|
1,068,376 |
|
|
994,368 |
|
US |
207,426 |
|
|
195,804 |
|
|
804,586 |
|
|
687,035 |
|
|
|
|
|
|
|
|
|
Total revenue |
482,269 |
|
|
458,139 |
|
|
1,872,962 |
|
|
1,681,403 |
|
|
|
|
|
|
|
|
|
KP Tissue Inc. |
Statements of Financial Position |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
|
December 31, 2022 |
|
|
$ |
|
|
$ |
|
Assets |
|
|
|
|
|
|
|
Current assets |
|
|
|
Dividends receivable |
1,793 |
|
|
- |
|
Distributions receivable |
- |
|
|
1,790 |
|
Income tax recoverable |
652 |
|
|
580 |
|
|
2,445 |
|
|
2,370 |
|
|
|
|
|
Non-current assets |
|
|
|
Investment in associate |
68,162 |
|
|
79,338 |
|
|
|
|
|
Total assets |
70,607 |
|
|
81,708 |
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
Current liabilities |
|
|
|
Dividend payable |
1,793 |
|
|
1,790 |
|
Payable to investee |
457 |
|
|
170 |
|
|
2,250 |
|
|
1,960 |
|
Non-current liabilities |
|
|
|
Deferred income taxes |
- |
|
|
5,718 |
|
|
|
|
|
Total liabilities |
2,250 |
|
|
7,678 |
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
Common shares |
22,560 |
|
|
22,379 |
|
Contributed surplus |
144,819 |
|
|
144,819 |
|
Deficit |
(115,027 |
) |
|
(108,008 |
) |
Accumulated other comprehensive income |
16,005 |
|
|
14,840 |
|
|
|
|
|
Total equity |
68,357 |
|
|
74,030 |
|
|
|
|
|
Total liabilities and equity |
70,607 |
|
|
81,708 |
|
|
|
|
|
KP Tissue Inc. |
Statements of Income (Loss) |
(thousands of Canadian dollars, except share and per share
amounts) |
|
|
|
|
|
|
|
|
|
3-monthperiod endedDecember 31, 2023 |
|
|
3-monthperiod endedDecember 31, 2022 |
|
|
12-monthperiod endedDecember 31, 2023 |
|
|
12-monthperiod endedDecember 31, 2022 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
Share of income (loss) |
2,212 |
|
|
2,339 |
|
|
(697 |
) |
|
(8,086 |
) |
Depreciation of fair value increments |
(279 |
) |
|
(1,271 |
) |
|
(1,165 |
) |
|
(5,213 |
) |
|
|
|
|
|
|
|
|
Equity income (loss) |
1,933 |
|
|
1,068 |
|
|
(1,862 |
) |
|
(13,299 |
) |
Dilution gain |
245 |
|
|
269 |
|
|
1,032 |
|
|
752 |
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
2,178 |
|
|
1,337 |
|
|
(830 |
) |
|
(12,547 |
) |
|
|
|
|
|
|
|
|
Current tax expense (recovery) |
215 |
|
|
38 |
|
|
215 |
|
|
(410 |
) |
Deferred tax expense (recovery) |
- |
|
|
2,289 |
|
|
3,892 |
|
|
(1,888 |
) |
|
|
|
|
|
|
|
|
Income tax expense (recovery) |
215 |
|
|
2,327 |
|
|
4,107 |
|
|
(2,298 |
) |
|
|
|
|
|
|
|
|
Net income (loss) |
1,963 |
|
|
(990 |
) |
|
(4,937 |
) |
|
(10,249 |
) |
|
|
|
|
|
|
|
|
Basic earnings (loss) per share |
0.20 |
|
|
(0.10 |
) |
|
(0.50 |
) |
|
(1.03 |
) |
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding |
9,962,907 |
|
|
9,944,972 |
|
|
9,955,981 |
|
|
9,936,187 |
|
|
|
|
|
|
|
|
|
KP Tissue Inc. |
Statements of Cash Flows |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
3-monthperiod endedDecember 31, 2023 |
|
|
3-monthperiod endedDecember 31, 2022 |
|
|
12-monthperiod endedDecember 31, 2023 |
|
|
12-monthperiod endedDecember 31, 2022 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Cash flows from (used in) operating
activities |
|
|
|
|
|
|
|
Net income (loss) |
1,963 |
|
|
(990 |
) |
|
(4,937 |
) |
|
(10,249 |
) |
Items not affecting cash |
|
|
|
|
|
|
|
Equity loss (income) |
(1,933 |
) |
|
(1,068 |
) |
|
1,862 |
|
|
13,299 |
|
Dilution gain |
(245 |
) |
|
(269 |
) |
|
(1,032 |
) |
|
(752 |
) |
Income tax expense (recovery) |
215 |
|
|
2,327 |
|
|
4,107 |
|
|
(2,298 |
) |
Total items not affecting cash |
(1,963 |
) |
|
990 |
|
|
4,937 |
|
|
10,249 |
|
|
|
|
|
|
|
|
|
Net change in non-cash working capital |
424 |
|
|
- |
|
|
287 |
|
|
(76 |
) |
Tax refunds (payments), net |
(424 |
) |
|
- |
|
|
(287 |
) |
|
38 |
|
Tax Distribution received, net |
- |
|
|
- |
|
|
- |
|
|
38 |
|
|
|
|
|
|
|
|
|
Net cash from (used in) operating activities |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
Dividends received, net |
1,742 |
|
|
- |
|
|
6,984 |
|
|
- |
|
Partnership unit distributions received, net |
- |
|
|
1,731 |
|
|
- |
|
|
6,617 |
|
|
|
|
|
|
|
|
|
Net cash from investing activities |
1,742 |
|
|
1,731 |
|
|
6,984 |
|
|
6,617 |
|
|
|
|
|
|
|
|
|
Cash flows used in financing activities |
|
|
|
|
|
|
|
Dividends paid, net |
(1,742 |
) |
|
(1,731 |
) |
|
(6,984 |
) |
|
(6,617 |
) |
|
|
|
|
|
|
|
|
Net cash used in financing activities |
(1,742 |
) |
|
(1,731 |
) |
|
(6,984 |
) |
|
(6,617 |
) |
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents during
the period |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - Beginning
of period |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - End
of period |
- |
|
|
- |
|
|
- |
|
|
- |
|
KP Tissue (TSX:KPT)
過去 株価チャート
から 10 2024 まで 11 2024
KP Tissue (TSX:KPT)
過去 株価チャート
から 11 2023 まで 11 2024